Lisocabtagene maraleucel is a medicine that treats what

Lisocabtagene（Lisocabtagene maraleucel), trade nameBreyanzi, is a cell-based gene therapy mainly used to treat B-cell lymphoma, especially large B-cell lymphoma (LBCL; non-Hodgkin lymphoma), including diffuse largeB-cell lymphoma (DLBCL) and follicular lymphoma 3B. The drug is indicated for adult patients who meet certain criteria, such as those with refractory disease after first-line chemoimmunotherapy or who have relapsed within 12 months of treatment. In addition, this drug can also be used if the patient is not suitable for hematopoietic stem cell transplantation (HSCT) due to comorbidities or age.

Lisocabbutanol is also indicated for several other types of cancer, including relapsed or refractory chronic lymphocytic leukemia (CLL) and small lymphocytic lymphoma (SLL), in which patients must undergo at least two courses of treatment. In addition, the drug is also suitable for patients with relapsed or refractory follicular lymphoma (FL) and mantle cell lymphoma (MCL), provided that the patient has received multiple previous systemic therapies.

In terms of side effects, lisocabeta root may cause allergic reactions, serious infections, low blood cell counts, and a weakened immune system. The most common side effects include a decrease in neutrophils, red blood cells, or platelets, and cytokine release syndrome, a potentially life-threatening condition characterized by fever, vomiting, shortness of breath, pain, and hypotension. In addition, common adverse reactions when treating follicular lymphoma include symptoms such as headache, musculoskeletal pain, fatigue, constipation, and fever.

As a chimeric antigen receptor (CAR) T-cell (CAR-T) therapy, lisocabetagen is the third gene therapy approved by the U.S. Food and Drug Administration (FDA) for certain types of non-Hodgkin lymphoma. Its innovation and efficacy bring new hope to many patients with difficult-to-treat blood cancers. In conclusion, the use of lisocabeta root provides a new treatment option for patients with hematological diseases, although potential side effects need to be paid close attention to.

Reference materials:https://www.breyanzi.com/